Drug Trial Radar · NCT01106586
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Last checked: Nov 19, 2026Latest source record: Nov 11, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
708
Actual
Start
Apr 2010
Primary completion
Sep 2011
Study completion Sep 2014
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Apr 20, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of Stribild®, a single tablet regimen (STR) containing fixed doses of elvitegravir (EVG)/cobicistat (COBI \[GS-9350\])/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) versus ritonavir-boosted atazanavir (ATV/r) plus the standard of care nucleoside reverse transcriptase inhibitor (NRTI) backbone FTC/TDF (Truvada®). ATV/r + FTC/TDF was selected as the active comparator for this study as it is a preferred protease inhibitor-based regimen in guidelines for the treatment of HIV-1 infected, antiretroviral treatment-naive adults.
Conditions
- HIV
- HIV Infections
Interventions
StribildDrug
Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
ATVDrug
Atazanavir 300 mg capsule administered orally once daily
RitonavirDrug
Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
FTC/TDFDrug
FTC/TDF 200/300 mg tablet administered orally once daily
Stribild PlaceboDrug
Placebo to match Stribild administered orally once daily
ATV PlaceboDrug
Placebo to match ATV administered orally once daily
RTV PlaceboDrug
Placebo to match RTV administered orally once daily
FTC/TDF PlaceboDrug
Placebo to match FTC/TDF administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48Time frame: Week 48
Locations
146 sites in 17 countries. Site status is shown where the registry gives one.
Spectrum Medical Group
Phoenix, Arizona
Health for Life Clinic PLLC
Little Rock, Arkansas
AHF Research Center
Beverly Hills, California
CSI Clinical Trials, Inc.
Costa Mesa, California
Apex Research, LLC
Denver, California
Kaiser Permanente Hospital
Hayward, California
Living Hope Clinical Foundation
Long Beach, California
Kaiser Permanente
Los Angeles, California
Los Angeles Gay and Lesbian Center DBA Jeffrey Goodman Special Care Clinic
Los Angeles, California
Peter J Ruane, MD, Inc
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Anthony Mills MD Inc
Los Angeles, California
Orange Coast Medical Group
Newport Beach, California
Alameda County Medical Center
Oakland, California
East Bay AIDS Center
Oakland, California
Stanford University
Palo Alto, California
University of California, Davis Medical Center
Sacramento, California
Kaiser Permanente Medical Group
Sacramento, California
La Playa Medical Group and Clinical Research
San Diego, California
Metropolitan Medical
San Francisco, California
Kaiser Permanente Medical Center, Clinical Trials Unit
San Francisco, California
National Jewish Health
Denver, Colorado
Yale University HIV Clinical Trials Program
New Haven, Connecticut
The Stamford Hospital
Stamford, Connecticut
Dupont Circle Physicians Group
Washington D.C., District of Columbia
Whitman Walker Clinic
Washington D.C., District of Columbia
Capital Medical Associates, PC
Washington D.C., District of Columbia
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia
Therafirst Medical Center
Fort Lauderdale, Florida
Broward Health/Comprehensive Care Center
Fort Lauderdale, Florida
Gary J. Richmond,M.D., P.A.
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
The Kinder Medical Group
Miami, Florida
Wohlfeiler, Piperato and Associates, LLC
Miami Beach, Florida
Orlando Immunology Center
Orlando, Florida
IDOCF/ ValueHealthMD, LLC
Orlando, Florida
University of South Florida HIV Clinical Research Unit / Hillsborough County Health Department
Tampa, Florida
Infectious Disease Research Institute Inc.
Tampa, Florida
St. Joseph's Comprehensive Research Institute
Tampa, Florida
Treasure Coast Infectious Disease Consultants
Vero Beach, Florida
Showing 40 of 146 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.